Yahoo
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today prov
Yahoo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Yahoo
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers. “Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextC
Yahoo
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of
Yahoo
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website a
Yahoo
BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfec
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALT | 36.11% | $368.13M | -48.55% | 0.00% |
CHMI | 28.98% | $101.20M | -7.78% | 19.61% |
CRBU | 27.14% | $80.08M | -81.60% | 0.00% |
W | 25.59% | $4.28B | -45.97% | 0.00% |
RCKT | 25.00% | $671.77M | -75.23% | 0.00% |
ARR | 24.84% | $1.34B | -13.44% | 17.58% |
GILT | 24.69% | $358.07M | +4.49% | 0.00% |
VIK | 24.65% | $18.58B | +74.88% | 0.00% |
TBCH | 24.52% | $300.76M | -14.63% | 0.00% |
SRPT | 23.92% | $6.06B | -50.78% | 0.00% |
VIRC | 23.69% | $152.79M | -20.71% | 1.07% |
KYMR | 23.63% | $1.71B | -29.01% | 0.00% |
VTYX | 23.56% | $75.40M | -79.54% | 0.00% |
CVNA | 23.53% | $30.40B | +174.66% | 0.00% |
NAVI | 23.13% | $1.33B | -24.67% | 5.41% |
RNA | 23.12% | $3.58B | +11.75% | 0.00% |
NPWR | 23.11% | $192.66M | -76.55% | 0.00% |
CLLS | 23.00% | $90.84M | -54.84% | 0.00% |
OLO | 22.84% | $1.03B | +19.27% | 0.00% |
GBIO | 22.59% | $24.81M | -91.01% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -12.66% | $416.76M | 1.43% |
TAIL | -12.45% | $87.65M | 0.59% |
TPMN | -11.80% | $33.32M | 0.65% |
VIXY | -11.39% | $195.31M | 0.85% |
SMB | -9.91% | $265.76M | 0.07% |
CCOR | -8.47% | $64.12M | 1.18% |
IYK | -8.33% | $1.53B | 0.4% |
CTA | -7.53% | $978.30M | 0.76% |
KMLM | -7.26% | $218.49M | 0.9% |
USCI | -6.92% | $240.82M | 1.07% |
PWZ | -6.71% | $703.30M | 0.28% |
CPER | -6.54% | $200.09M | 0.97% |
COM | -5.98% | $242.21M | 0.72% |
VRIG | -5.78% | $1.44B | 0.3% |
GOVT | -5.65% | $26.61B | 0.05% |
FMF | -5.50% | $154.59M | 0.95% |
XLP | -5.45% | $16.87B | 0.09% |
DBA | -5.25% | $829.48M | 0.93% |
BCD | -5.10% | $250.79M | 0.3% |
KXI | -5.09% | $725.04M | 0.41% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NOC | -16.94% | $74.14B | +12.07% | 1.60% |
KMB | -16.51% | $47.39B | +13.36% | 3.37% |
PG | -14.06% | $397.45B | +8.55% | 2.32% |
LITB | -14.00% | $41.93M | -46.48% | 0.00% |
CBOE | -13.75% | $23.50B | +25.53% | 1.05% |
KDP | -12.90% | $47.68B | +13.32% | 2.55% |
CLX | -12.78% | $18.19B | +0.54% | 3.24% |
CHD | -12.17% | $26.66B | +5.00% | 1.03% |
THS | -12.14% | $1.32B | -29.19% | 0.00% |
GFL | -12.07% | $19.03B | +43.82% | 0.12% |
NGL | -11.48% | $615.18M | -18.67% | 0.00% |
STVN | -11.26% | $5.72B | -30.31% | 0.28% |
CME | -11.04% | $94.61B | +23.82% | 3.89% |
OR | -10.96% | $3.92B | +27.61% | 0.88% |
FINV | -10.38% | $1.46B | +95.49% | 2.47% |
KHC | -10.10% | $36.01B | -19.37% | 5.15% |
PHG | -10.04% | $22.98B | +25.80% | 0.00% |
LX | -9.91% | $1.34B | +474.59% | 1.39% |
CPB | -9.91% | $11.75B | -8.27% | 3.73% |
LOAR | -9.79% | $7.19B | +174.46% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GD | 0.01% | $74.63B | -5.37% | 2.09% |
WHD | 0.01% | $3.23B | -7.75% | 1.25% |
INSM | -0.01% | $13.29B | +165.32% | 0.00% |
PDCO | -0.01% | $2.77B | +17.86% | 2.49% |
HTHT | 0.02% | $11.68B | -9.16% | 0.00% |
R | 0.03% | $6.33B | +26.85% | 2.24% |
JKHY | 0.07% | $13.42B | +8.13% | 1.20% |
BHP | -0.07% | $121.44B | -18.63% | 5.30% |
CACI | -0.08% | $8.77B | +5.80% | 0.00% |
DB | 0.08% | $46.21B | +50.71% | 2.11% |
GLPI | 0.09% | $13.90B | +11.86% | 6.14% |
AMKR | 0.09% | $4.60B | -39.63% | 1.98% |
TFX | -0.10% | $6.56B | -34.16% | 0.98% |
DAR | -0.10% | $5.24B | -23.49% | 0.00% |
HEI.A | -0.11% | $29.55B | +39.68% | 0.11% |
NMM | 0.12% | $1.17B | -8.03% | 0.54% |
TKO | 0.13% | $12.93B | +71.22% | 0.25% |
TCPC | 0.13% | - | - | 16.25% |
OGE | -0.14% | $9.34B | +35.10% | 3.61% |
FRSH | 0.14% | $4.40B | -17.38% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
LGOV | 0.05% | $664.16M | 0.67% |
DTH | -0.09% | $371.46M | 0.58% |
THD | -0.11% | $187.32M | 0.59% |
REZ | -0.11% | $858.68M | 0.48% |
ULST | 0.11% | $585.14M | 0.2% |
GCOW | -0.15% | $2.19B | 0.6% |
FLIA | 0.17% | $631.63M | 0.25% |
WEAT | 0.24% | $115.75M | 0.28% |
FLGV | 0.35% | $959.69M | 0.09% |
GOVZ | 0.36% | $296.64M | 0.1% |
EPOL | -0.39% | $327.25M | 0.6% |
IBTF | 0.40% | $2.22B | 0.07% |
EZU | 0.46% | $8.77B | 0.51% |
IDV | 0.46% | $4.37B | 0.49% |
FEZ | 0.50% | $4.52B | 0.29% |
SCHQ | 0.53% | $950.81M | 0.03% |
BSMW | 0.54% | $101.29M | 0.18% |
IGOV | 0.54% | $432.75M | 0.35% |
EWQ | 0.55% | $480.13M | 0.5% |
MMIN | 0.58% | $473.48M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTC | 36.09% | $3.28B | 0.15% |
ETH | 31.24% | $1.29B | 0% |
QETH | 30.90% | $14.36M | 0.25% |
EZET | 30.84% | $22.46M | 0% |
CETH | 30.73% | $10.49M | 0% |
ETHW | 30.63% | $178.76M | 0% |
FETH | 30.53% | $762.75M | 0.25% |
ETHA | 30.49% | $2.27B | 0.25% |
ETHV | 30.45% | $87.97M | 0% |
GNOM | 26.45% | $47.13M | 0.5% |
CPRJ | 25.72% | $48.38M | 0.69% |
FCOM | 24.49% | $1.38B | 0.084% |
VOX | 23.71% | $4.40B | 0.09% |
XBI | 23.39% | $4.76B | 0.35% |
XLC | 23.04% | $20.35B | 0.09% |
IWC | 22.29% | $797.08M | 0.6% |
IBB | 22.16% | $5.61B | 0.45% |
RECS | 22.14% | $2.27B | 0.15% |
IBUY | 21.89% | $154.71M | 0.65% |
PTH | 21.62% | $107.91M | 0.6% |
Current Value
$0.391 Year Return
Current Value
$0.391 Year Return